KIT and neoplasm: It demonstrated an ORR of 22%–30% in the overall population and 24%–37% in patients with KIT exon 11 mutations, when used as a second-line treatment for patients who progressed or were intolerant to Imatinib therapy, providing an opportunity for tumor reduction in these patients (Li et al., 2024a).